Image
Point-of-Care 101

Answering the Bell in Severe Asthma

New Pathways to Optimize Patient Outcomes

Clinical Practice Guidelines

Global Strategy for Asthma Management and Prevention.

Global Initiative for Asthma, 2021

Clinical Practice Tools

Centers for Disease Control and Prevention (CDC) Asthma Action Plans

These tools for asthma control were created following the evidence-based guidance published by the National Institutes of Health.        

Asthma Control Test (ACT)

This 5-question test evaluates asthma control over the past 4 weeks on a 5-point Likert scale. A score of <20 on the ACT suggests asthma that is uncontrolled.

Nathan RA, et al. J Allergy Clin Immunol. 2004;113(1):59-65.

Asthma Control Questionnaire (ACQ)

This 7-question assessment tool measures asthma control over the past 7 days. Six questions are self-administered by the patient, and 1 question requires a clinician’s input. Scores range from 1 (totally controlled) to 6 (severely uncontrolled).

Juniper EF, et al. Eur Respir J. 1999;14(4):902-907.

Asthma Therapy Assessment Questionnaire (ATAQ)

This 4-question test assesses asthma control over the past 4 weeks. Each question has a possible score of 0 or 1; if the sum of the 4 question scores is >1, the patient’s asthma may be uncontrolled.

Vollmer WM, et al. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1647-1652 

Shared Decision-Making Tool

The CHEST Foundation, Allergy and Asthma Network, and American College of Allergy, Asthma & Immunology (ACAAI) have developed a shared decision-making tool for adults with severe asthma so that they may work collaboratively with clinicians to improve self-management skills, choose the best treatment plan, and increase adherence.

Suggested Readings

Biologic therapies for severe asthma.

Brusselle GG, Koppelman GH. N Engl J Med. 2022;386(2):157-171.

Controversies in allergy: choosing a biologic for patients with severe asthma. 

Pavord ID, et al. J Allergy Clin Immunol Pract. 2022;10(2):410-419.

A rationale approach to compare and select biologic therapeutics in asthma.

Wang E, Wechsler ME. Ann Allergy Asthma Immunol. 2022. [Epub before print].

How to assess effectivness of biologics for asthma and what steps to take when there is not benefit.

Pepper AN, et al. J Allergy Clin Immunol Pract. 2021;9(3):1081-1088.

Biological therapies for asthma.

Couillard Castonguay S, Pavord ID. Enclopedia of Respiratory Medicine. 2021; 2nd ed (2): 411-434.

Tezepelumab in adults and adolescents with severe, uncontrolled asthma.

Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800-1809.

Efficacy and safety of itepekimab in patients with moderate-to-severe asthma.

Wechsler ME, et al. N Engl J Med. 2021;385(18):1656-1668.

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.

Diver S, et al. Lancet Respir Med. 2021; 9(11):1299-1312.

Patient Advoacy Organizations

Asthma and Allergy Foundatin of America (AAFA)

AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research.

American College of Allergy, Asthma & Immunology (ACAAI)

The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.

American Lung Assocation

The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.  The American Lung Assocation is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.

American Thoracic Society (ATS)

The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.

Chest Foundation

The CHEST Foundation creates trusted patient education resources and disease awareness campaigns that empower patients to engage in better managing their health.

Activity
New Insights Into Severe Asthma Pathophysiology and Treatment

Activity 1

Relevant Resources

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Clearing the Air

Improving Outcomes for Patients with COPD

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Improving Outcomes in Severe Asthma

A New Era in Precision Medicine

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

Clinical Issues in Severe Asthma

Consensus and Controversies on the Road to Precision Medicine

Breathing Life Into COPD Management

Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care

Clinical Issues in Severe Asthma

Debates and Discussions About Personalizing Patient Management

Advancing the Care of Severe Asthma

Differential Diagnosis, Multidisciplinary Management, and Patient Engagement

Focusing on Patients With Severe Asthma

From Guideline Recommendations to Daily Clinical Decision-Making

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

Marching Forward in Atopic Dermatitis

Digging Deep on Shared Decision-Making

Airing It Out

A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis

COPD in Managed Care

The Clinical and Utilization Benefits of Exacerbation Prevention

Finding the Right Path in Severe Asthma

Mechanistic Insights and Emerging Treatment Options

COPD Cases and Conversations

A Focus on Exacerbation Prevention

Demystifying New Evidence for COPD Management

Best Practices for Primary Care

Updates on Chronic Rhinosinusitis with Nasal Polyps

Evolving Best Practices for Patient Management

A Breath of Fresh Air in Pediatric Asthma

Shared Decision-making in the Era of Biologics

Swimming Upstream in Severe Asthma

New Pathways to Patient Management

Where are We Now In Moderate-to-Severe Asthma?

From Comprehensive Patient Evaluations to Individualized Evidence-based Care

COPD Cases & Conversations

Preventing COPD Exacerbations to Improve Outcomes

Comprehensive Management in COPD

A Whole Patient Case Series

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Cause for Alarm

New Avenues to the Management of Severe Asthma

Getting Up To Speed In Moderate-To-Severe Asthma

Evolving Best Practices for Pediatric Patients

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Getting Low in Familial Hypercholesterolemia

Reducing LDL-C and a Lifetime of Cardiovascular Risk

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Targeting Clear Horizons

Finding the Path in Chronic Rhinosinusitis with Nasal Polyps

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Clinical Issues in Severe Asthma

Debates and Discussions About New Upstream Treatment Avenues

Clearing the Way in Atopic Dermatitis

A Case-Based Update on Pediatric Patients